Dianthus Therapeutics (DNTH) Preferred Stock Liabilities (2017 - 2022)
Dianthus Therapeutics' quarterly Preferred Stock Liabilities came in at $118.0 million in Q4 2022, up 27.68% quarter-over-quarter from $92.4 million in Q4 2017.
Dianthus Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $118.0 million in Q4 2022.
- For the quarter ending Q4 2022, Preferred Stock Liabilities changed N/A year-over-year to $118.0 million; the trailing twelve-month figure through Dec 2022 stood at $118.0 million (changed N/A YoY), and the FY2022 full-year result was $118.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2022 stood at $118.0 million, up from $92.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $118.0 million in Q4 2022, with the low at $118.0 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Dianthus Therapeutics | 4.02 Bn | 3.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 118.02 Mn |
| Dec 31, 2017 | 92.44 Mn |